|Articles|March 15, 2002

BioPharm International

  • BioPharm International-03-15-2002
  • Volume 15
  • Issue 3

Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?

Author(s)Jill Wechsler

by Jill Wechsler, pp. 55-57, 60 The industry must ensure that manufacturing systems can produce high quality and consistent therapies, efforts that may lead to comparable "subsequent entry" products.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 24 years ago

Guest Editorial: Warning Letters ? A Symptom?

almost 24 years ago

The Importance of Freezing on Lyophilization Cycle Development

almost 24 years ago

Outsourcing Outlook: Using Earned-Value Analysis for Better Project Management

almost 24 years ago

Business Benefits of Computer Systems Validation

almost 24 years ago

Validation of Quantitative PCR Assays?Addressing Virus Contamination Concerns

almost 24 years ago

A System Developer's Approach to Validation

almost 24 years ago

Additional charts for the Zeid article, "Specifications and Manufacturing Change Control"

almost 24 years ago

Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!